Krystal Biotech (KRYS) traded higher Friday as the stock drew incremental bid interest into the next earnings catalyst and after recent bullish analyst actions reset upside targets for the name. The next earnings date is broadly flagged for May 11, 2026, keeping near-term focus on VYJUVEK demand, margin profile, and 2026 expense guidance sensitivity as investors look for confirmation that 2025’s profitability and revenue momentum can carry into 2026. (investing.com)

Recent research activity has been constructive for KRYS, including a maintained Strong Buy stance at Jefferies alongside a higher price target earlier this year. That supportive sell-side setup has helped keep dips bought, particularly as investors frame KRYS as a commercial-stage gene therapy company with multiple follow-on programs beyond its lead product. (stockanalysis.com)

Beyond earnings, investors continue to track progress in the company’s inhaled gene therapy program KB407 for cystic fibrosis, where interim Phase 1 data supported evidence of delivery/expression markers in the lungs and the company has pointed to upcoming steps toward the next CORAL study. On the commercial side, KRYS has been expanding the VYJUVEK launch outside the U.S., with reimbursement and rollout timing in major European markets remaining a key swing factor for 2026 expectations. (ir.krystalbio.com)

Near-term attention is likely to stay centered on (1) any pre-earnings revisions to expectations, (2) management commentary around international pricing/reimbursement cadence, and (3) updates on the timing and design of the next KB407 study. With the next earnings event approaching on May 11, positioning and headline sensitivity could remain elevated into the report. (investing.com)